Skip To Main Content
Murray Baron on Muck Rack

Murray Baron

Montreal
As seen in: Wiley Online Library, Annals of the Rheumatic Diseases, MDPI, The Globe and Mail, Arthritis Research & Therapy, Rheumatology, The Lancet, ersnet.org, The Journal of Rheumatology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Murray

Contact Murray, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Real‐World Safety and Effectiveness of JAK Inhibitors in Systemic Sclerosis: A Propensity‐Matched Study from the EUSTAR Cohort

|
By Stefano Di Donato, Marie‐Elise Truchetet, Marco Minerba, Oliver Distler, Yolanda Braun‐Moscovici, Christina Bergmann, Petros Sfikakis, Murray Baron, Silvia Bellando‐Randone, Lorenzo Dagna
| Wiley Online Library Verified
Real‐World Safety and Effectiveness of JAK Inhibitors in Systemic Sclerosis: A Propensity‐Matched Study from the EUSTAR Cohort - Di Donato - Arthritis Care & Research - Wiley Online Library
Open in Who Shared Issue with article?

Distinct Systemic Sclerosis Phenotypes Related to Ethnicity: An Opportunity to Personalize Care?

|
By Danick Goulet, Camille Guertin, Maggie M. Larche, Maggie J. Larché, Marie Hudson, May Y. Choi, Mohammed Osman, Janet Pope, Carter Thorne, Murray Baron, M. R. Baron, P.R. Fortin, M. Fr, Isabelle Ferdinand, M.Y. Choi, P. Docherty
| Wiley Online Library Verified
Open in Who Shared Issue with article?

Associations with, and predictors of, progression in systemic sclerosis-related interstitial lung disease: a scoping literature review

|
By Kathleen Morrisroe, Murray Baron
| ersnet.org
Introduction Systemic sclerosis (SSc), also known as scleroderma, is a rare, complex, multi-organ autoimmune disease of unknown aetiology. It is characterised by high morbidity and mortality resulting from its cardiopulmonary complications, especially interstitial lung disease (ILD), pulmonary arterial hypertension and cardiac involvement [1–3]. SSc-related ILD (SSc-ILD) occurs with a prevalence of 30–70% and displays a heterogenous disease course [4].
Open in Who Shared Issue with article?
See all 16 articles